Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

GALT US Equity

Galectin Therapeutics IncHealth Care · Pharmaceutical Preparations · CIK 1133416 · FY ends Dec 31
$3.67
+0.15 (+4.26%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-31described hereNOT effectiveNOT effectivedisclosedEDGAR

Item 3 · Legal Proceedings From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.

Item 9A · ICFR · Based on the evaluation, management concluded that our internal control over financial reporting was not effective as of December 31, 2025 as a result of the material weakness discussed in the paragraphs that follow below.

Item 9A · disclosure controls · Our management has concluded, based on their evaluation, that our disclosure controls and procedures were not effective as of December 31, 2025 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms due to the material weakness described below.In light of the material weakness described below, management performed additional analyses and other procedures to ensure that our consolidated financial statements were prepared in accordance with GAAP.

2024-12-312025-03-31as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.

Item 9A · ICFR · Based on the evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · Our management has concluded, based on their evaluation, that our disclosure controls and procedures were effective as of December 31, 2024 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

2023-12-312024-03-29as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.

Item 9A · ICFR · Based on the evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · Our management has concluded, based on their evaluation, that our disclosure controls and procedures were effective as of December 31, 2023 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

2022-12-312023-03-30as filednot extractednot extracteddisclosedEDGAR

Item 3 · From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.

Item 9A · ICFR · Based on the evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Our management has concluded, based on their evaluation, that our disclosure controls and procedures were effective as of December 31, 2022 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Item 9A · material weakness · We determined that this deficiency constitutes a "material weakness" in our internal control over financial reporting.

2021-12-312022-03-31as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.

Item 9A · ICFR · Based on the evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · Our management has concluded, based on their evaluation, that our disclosure controls and procedures were effective as of December 31, 2021 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.